To better understand and draw further conclusions on the role of MPZL3 as a bona fide CAM, future studies are needed to elucidate novel binding partners of MPZL3 in normal and cancer epithelial cells with focus on the N-terminal extracellular IgV and C-terminal cytoplasmic domains. Here, MPZL3 is linked to cancer.